Clinical Trial Pipeline
The NDC directory covers drugs that are already approved and marketed. This section tracks what is still in testing — by therapeutic area, phase and how the treatment is given.
Phase 3 — closest to approval
Large comparative studies, typically 1–3 years from an FDA decision. This is where tomorrow's NDC codes come from.
Phase 2 — in development
Mid-size studies testing whether the treatment actually works for the condition, usually 3–5 years out.
Phase 1 — early research
First-in-human safety and dosing work. Long-term, but every approved drug started here.
Browse the pipeline by therapeutic area
Each area maps to the same pharmacologic classes used in the NDC directory, so you can move between an approved drug and what is coming next.
GLP-1 Receptor Agonists (Diabetes & Weight)
Semaglutide, Tirzepatide, Liraglutide — diabetes & weight management therapies
Statins (Cholesterol & Cardio)
Atorvastatin, Rosuvastatin, Simvastatin — lipid-lowering & cholesterol control
SGLT2 Inhibitors (Kidney & Heart)
Empagliflozin, Dapagliflozin — glycaemic control, heart failure & chronic kidney disease
Monoclonal Antibodies & Immunotherapies
Pembrolizumab, Nivolumab, Adalimumab — targeted oncology & autoimmune biologics
Beta Blockers (Blood Pressure)
Metoprolol, Atenolol, Propranolol — hypertension, angina & arrhythmia management
NSAIDs (Pain & Inflammation)
Ibuprofen, Naproxen, Celecoxib — pain relief, anti-inflammatory & antipyretic
CNS Stimulants (ADHD)
Amphetamine/Dextroamphetamine, Methylphenidate — ADHD & narcolepsy
SSRIs & Mood Therapies
Sertraline, Escitalopram, Fluoxetine — major depression & anxiety disorders
Clinical Trial Coding vs. Commercial Billing
How medical coding standardizes safety data in clinical research before drugs enter the NDC & J-Code directories.
MedDRA & WHODrug
During clinical trials, adverse events (AEs) and medical conditions are standardized using the 5-tier MedDRA hierarchy. Concomitant medications are classified via the WHODrug global dictionary to monitor safety and drug-drug interactions for FDA/EMA submissions.
NDC, HCPCS & CPT Claims
Once a candidate proves safety and efficacy in Phase 3 trials and receives FDA approval (NDA/BLA), it transitions to commercial billing. The manufacturer lists the product for an 11-digit NDC, CMS assigns a permanent HCPCS J-Code, and payers reimburse claims via Box 24 line items.
Already approved? Look up the NDC
Once a treatment is marketed it gets a National Drug Code, a J-Code and a CPT administration code — all searchable in the directory.